<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403869</url>
  </required_header>
  <id_info>
    <org_study_id>CEL-CMM-2013-01</org_study_id>
    <nct_id>NCT02403869</nct_id>
  </id_info>
  <brief_title>Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy</brief_title>
  <acronym>DD-CMM</acronym>
  <official_title>Study of Quality of Life in Patients With Metastatic Breast Cancer Treated With Second-line Monochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-authorization, prospective follow-up, multi-centre, national study to estimate
      definitive deterioration in the quality of life in patients with metastatic breast cancer
      treated with second-line monochemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-authorization, prospective, multi-centre study in Metastatic Breast Cancer patients
      treated with second-line monochemotherapy.

      A total of 200 patients are expected to be recruited from 32 Spanish sites.

      In this study the results perceived by patients will be compiled to assess overall Quality of
      Life (QoL) in MBC patients treated with second-line monochemotherapy, using the EORTC QLQ-C30
      questionnaire (European Organization for Research and Treatment of Cancer Quality of Life
      Questionnaire) and its modules EORTC QLQ-BR23 (EORTC Breast Cancer specific) and EORTC
      QLQ-CIPN20 (EORTC Chemotherapy-Induced Peripheral Neuropathy).

      Patients will be evaluated at the time of acceptance to participate in the study after
      signing the informed consent and will be tracked every three months during treatment with
      second-line monochemotherapy, coinciding with routine assessments within normal clinical
      practice. When the patient completes treatment with second-line chemotherapy he/she will
      enter the post-treatment period, with follow-up at six and 12 months after completion of
      treatment. Also, patients will be followed to assess survival until the end of the study (30
      months after enrolment of the last patient in the study). Follow-up time has been established
      based on the median survival of patients with MBC
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 12, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Definitive deterioration at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with definitive deterioration at six months after initiation of second-line mono-chemotherapy for MBC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Definitive deterioration at 3 months</measure>
    <time_frame>3 Months</time_frame>
    <description>Description Proportion of patients with definitive deterioration at 3 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definitive deterioration at 9 months</measure>
    <time_frame>9 Months</time_frame>
    <description>Proportion of patients with definitive deterioration at 9 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definitive deterioration at 12 months</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion of patients with definitive deterioration at 12 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Definitive deterioration (TTDD)</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Estimated median TTDD using the actuarial method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Estimated overall survival using the Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTDD as a prognostic factor</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Determine if TTDD is an independent prognostic factor for overall survival using Cox regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Comparison of the mean score of the scales of the EORTC QLQ-C30, EORTC QLQ-BR23 and between patients ≥70 years and &lt;70 years at baseline, every 3 months approximately and at the time of disease progression or completion of treatment for other reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life every 3 months</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Score in the scales of the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires at baseline, every 3 months approximately and at the time of disease progression or completion of treatment for other reasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy-induced peripheral neuropathy</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Incidence, management and duration of chemotherapy-induced peripheral neuropathy at baseline, every 3 months approximately up to disease progression and at 6 and 12 months after completion of second-line chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy-induced peripheral neuropathy in the EORTC QLQ-CIPN20</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Assess the effect of chemotherapy-induced peripheral neuropathy in the EORTC QLQ-CIPN20 quality of life questionnaire at baseline, every 3 months approximately up to disease progression or completion of treatment for other reasons and at 6 and 12 months after completion of second-line chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definitive deterioration</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Comparison of the proportion of patients with definitive deterioration at every 3 months approximately up to disease progression or completion of treatment for other reasons in patients with ECOG 0-1 and ECOG 2-3, using the chi-squared test.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">148</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        MBC patients, older than or equal to 18 years of age, on second line of treatment with
        chemotherapy regimens in monotherapy and Her-2/neu-negative status
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who give their written informed consent.

          -  Patients with metastatic breast cancer who start treatment with second-line
             monochemotherapy.

          -  Patients of both sexes, at least 18 years of age and of any race.

          -  Patients with life expectancy longer than or equal to 12 weeks.

          -  Patients with histological or cytological diagnosis of Her-2/neu negative breast
             adenocarcinoma.

          -  Patients with ability enough to understand the questionnaires.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Patients who have been treated with chemotherapy in the last three weeks

          -  Patients who refuse to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorena Pellín, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <state>Andalucía</state>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <state>Andalucía</state>
        <zip>14012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <state>Andalucía</state>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma Mallorca</city>
        <state>Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Canarias</name>
      <address>
        <city>La Laguna, Santa Cruz De Tenerife</city>
        <state>Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud. Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Castilla La Mancha</state>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Burgos</name>
      <address>
        <city>Burgos</city>
        <state>Castilla Y León</state>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de León</name>
      <address>
        <city>León</city>
        <state>Castilla Y León</state>
        <zip>24001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bierzo</name>
      <address>
        <city>León</city>
        <state>Castilla Y León</state>
        <zip>24404</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Teknon</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Joan de Reus</name>
      <address>
        <city>Reus, Tarragona</city>
        <state>Cataluña</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporación Sanitaria Parc Taulí- Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Cataluña</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Elche</name>
      <address>
        <city>Elche</city>
        <state>Comunidad Valenciana</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026:</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Infanta Cristina de Badajoz</name>
      <address>
        <city>Badajoz</city>
        <state>Extremadura</state>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <state>Extremadura</state>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra-Montecelo</name>
      <address>
        <city>Pontevedra</city>
        <state>Galicia</state>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofía</name>
      <address>
        <city>Madrid</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Monotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>second line</keyword>
  <keyword>treatment</keyword>
  <keyword>Her 2 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

